Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis.

Donnez J, Dewart PJ, Hedon B, Perino A, Schindler AE, Blumberg J, Querleu D

Fertility and sterility1 Feb 2004Cited by 16 (Europe PMC)

PMID14967363DOI10.1016/j.fertnstert.2003.07.013PepBankPUB-14967363

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with endometriosis, medical castration at day 84 occurred in 97% with three-month versus 94% with 28-day triptorelin.
In plain wordsIn women with endometriosis, medical castration occurred in 97% with three-month versus 94% with 28-day triptorelin at day 84.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableMedical castration at day 84
Study
n = 146
Comparator
28-day triptorelin formulation
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Measurements
Medical castration
97%
3-month formulation day 84
Medical castration
94%
28-day formulation day 84
Source sentences
Summary
Ninety-seven percent of patients given the 3-month formulation and 94% of those given the 28-day formulation were in a state of medical castration on day 84.
2 context sentences(design, population, supporting numbers)
Summary · context
A phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis.
Summary · context
As part of two parallel treatment groups, 72 women were given a single intramuscular injection of 3-month triptorelin SR, and 74 women were given one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1496736301
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with endometriosis, the three-month triptorelin formulation achieved castration sooner than the 28-day formulation.
In plain wordsIn women with endometriosis, three-month triptorelin achieved medical castration sooner than 28-day triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTime to medical castration
Study
n = 146
Comparator
28-day triptorelin formulation
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
The mean time to achieve castration was shorter for the 3-month formulation, and the duration of castration was significantly longer.
2 context sentences(design, population, supporting numbers)
Summary · context
A phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis.
Summary · context
As part of two parallel treatment groups, 72 women were given a single intramuscular injection of 3-month triptorelin SR, and 74 women were given one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1496736302
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with endometriosis, the three-month triptorelin formulation maintained castration significantly longer than the 28-day formulation.
In plain wordsIn women with endometriosis, three-month triptorelin maintained medical castration longer than 28-day triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseDuration of medical castration
Study
n = 146
Comparator
28-day triptorelin formulation
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
The mean time to achieve castration was shorter for the 3-month formulation, and the duration of castration was significantly longer.
2 context sentences(design, population, supporting numbers)
Summary · context
A phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis.
Summary · context
As part of two parallel treatment groups, 72 women were given a single intramuscular injection of 3-month triptorelin SR, and 74 women were given one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1496736303
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with endometriosis, FSH parameters were comparable but not always identical between three-month and 28-day triptorelin formulations.
In plain wordsIn women with endometriosis, FSH measures were comparable but not always identical between three-month and 28-day triptorelin formulations.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
MixedFSH parameters
Study
n = 146
Comparator
28-day triptorelin formulation
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
The FSH and LH parameters were comparable, though not always identical.
2 context sentences(design, population, supporting numbers)
Summary · context
A phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis.
Summary · context
As part of two parallel treatment groups, 72 women were given a single intramuscular injection of 3-month triptorelin SR, and 74 women were given one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1496736304
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In women with endometriosis, LH parameters were comparable but not always identical between three-month and 28-day triptorelin formulations.
In plain wordsIn women with endometriosis, LH measures were comparable but not always identical between three-month and 28-day triptorelin formulations.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
MixedLH parameters
Study
n = 146
Comparator
28-day triptorelin formulation
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
The FSH and LH parameters were comparable, though not always identical.
2 context sentences(design, population, supporting numbers)
Summary · context
A phase II, prospective, randomized, multicenter, open study was conducted in two parallel groups of women with endometriosis.
Summary · context
As part of two parallel treatment groups, 72 women were given a single intramuscular injection of 3-month triptorelin SR, and 74 women were given one intramuscular injection of 28-day triptorelin SR every 28 days for 3 months.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1496736305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis.

Summary

Results from this study5

Studies that did not test the peptide alone5

Version history

Subjects

Publication types

MeSH terms